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B cells are capable of producing antibodies of diverse antigen specificities and 
effector functions to counter infection by a wide range of pathogens.  The diversification 
of immunoglobulin (Ig) is achieved through a series of programmed DNA recombination 
and mutagenic events during B cell maturation.  A key factor involved in the Ig 
diversification process is Activation Induced Cytidine Deaminase (AID).  AID is a B 
cell specific enzyme that is critical for three distinct pathways of Ig diversification: class 
switch recombination, somatic hypermutation and Ig gene conversion.  AID functions 
by deaminating cytosine to uracil in target DNA at the Ig loci.  Although essential for 
effective immunity, the mutagenic activity of AID needs to be confined to the Ig loci in 
order to protect genomic integrity, but the underlying mechanism is not fully understood. 
In this study, I show that two lymphoid specific transcription factors, PU.1 and IRF4, 
play important roles in regulating AID function in chicken B cells.  PU.1 and IRF4 have 
been implicated in many aspects of B cell development and function.  The two factors 
could form a heterodimer and regulate target gene expression cooperatively.  However, 
we found that PU.1 and IRF4 appear to have different impacts on AID function.  We 
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show that PU.1 is important for the expression of AID gene in chicken B cells, and the 
regulation appears to involve direct interaction of PU.1 with the AID gene.  By 
comparison, IRF4 plays a minor role in AID expression.  On the other hand, both PU.1 
and IRF4 are required for efficient gene conversion that is mediated by AID at the Igλ 
locus.  Moreover, the gene dosage of PU.1 is critical for AID function, since a severe 
gene conversion defect is observed in PU.1
+/-
 cells.  The function of PU.1 and IRF4 in 
AID-mediated gene conversion involves binding sites for the PU.1/IRF4 complex within 
a regulatory element at the Igλ locus.  Future studies will be directed at understanding 
how PU.1 and IRF4 regulate AID-mediated gene conversion. 
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1.1 THE MOLECULAR MECHANISMS OF IMMUNOGLOBULIN (IG) DIVERSIFICATION. 
In order to defend the host against infections, the immune system has evolved 
strategies to recognize and destroy a wide range of pathogens.  A major part of the 
immune response is mediated by B cells, which are capable of producing a large 
repertoire of antibodies with distinct antigen-binding sites and effector functions.  
Antibody diversity is achieved through a series of programmed DNA recombination and 
mutagenic events that take place during various stages of B-cell maturation, including the 
V(D)J recombination, Ig gene conversion, somatic hypermutation, and class switch 
recombination.  Following is a description of these Ig diversification mechanisms.  
 
1.1.1 V(D)J recombination 
Each antibody molecule consists of two Ig heavy chains (IgH) and two Ig light 
chains (IgL) [1], which can be divided into the variable (VH and VL) and constant regions 
(CH and CL) [1].  The variable regions associate with antigens [1], whereas the CH 
region mediates the effector functions [1].  The coding sequences for the Ig variable 
regions are assembled by joining a set of variable (V), diversity (D), and joining (J) gene 
segments [1] through V(D)J recombination during the early stage of B-cell maturation in 
the bone marrow (Fig. 1.1A).  The recombination reaction is catalyzed by a recombinase 
that is encoded by the recombination-activating genes 1 and 2 (RAG1 and RAG2) [2].  
The two proteins constitute an endonuclease that cleaves the recombination recognition 
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sequences (RSSs) at the border of the V, D, and J gene segments [2], and the resultant 
double-stranded DNA breaks (DSBs) are joined by the nonhomologous end joining 
(NHEJ) system to form the recombination product [2].  V(D)J recombination introduces 
diversity in antibody variable region at two levels.  First, there are many different V, D, 
and J gene segments at the IgH and IgL loci, and the random joining of these gene 
segments gives rise to a tremendous amount of combinatorial diversity of the assembled 
V region coding sequences.  Moreover, the combination of different pairs of heavy and 
light chains further increases the range of antigen-binding sites.  Second, during the 
repair of the RAG-mediated double stranded DNA breaks, nucleotides can be added or 
lost at the junctions between the gene segments [1], and the imprecise junction is another 
major contributor to the diversity of antibody binding site.  For these reasons, a diverse 





Figure 1.1.  V(D)J recombination at the murine IgH locus (adapted from reference 2).  A. The 
germline configuration of murine IgH locus (not to scale).  iE and 3’RR refer to intronic enhancer 
and 3’ regulatory regions, respectively.  Cµ and Cα refer to the constant region of µ and α heavy 
chains.  B. Scheme of V(D)J recombination at the IgH locus.  RSS is composed of a conserved 
heptamer and a nonamer motif with a spacer of either 23 or 12-bp.  The spacer length (23 or 12-bp) 
is indicated above the RSSs in the figure.  Recombination takes place between an RSS of 12-bp 
spacer and an RSS of 23-bp spacer.  This phenomenon is called the 12-23 rule.   
 
 
In spite of the apparent diversity of V(D)J recombination, the reaction proceeds in 
a temporally ordered fashion during B-cell maturation in the bone marrow [1].  The IgH 
locus rearranges prior to the IgL loci, and takes place at the pro-B cell stage.  After the 
successful completion of the IgH rearrangement, the expressed IgH protein associates 















with the surrogate light chain to form the pre-B cell receptor, which signals the B-cell 
precursor to progress to the pre-B cell stage and carry out the rearrangement of the IgL 
loci.   
There are two isotypes of IgL: κ and λ, and the κ locus generally rearranges prior 
to the λ locus.  Besides the differential timing of the heavy and light chain 
rearrangements, the different gene segments also undergo V(D)J recombination in a 
defined order.  Within the IgH locus, the D and J gene segments are recombined first, 
and V is subsequently joined to the combined DJ gene segments (Fig. 1.1B).  A third 
level of complexity is the differential rearrangements of the two alleles of IgH and IgL.  
One allele of IgH or IgL is randomly chosen to undergo V(D)J recombination first.  If 
the first rearrangement results in the formation of a functional coding sequence, the 
second allele is precluded from further rearrangement.  This phenomenon is called 
allelic exclusion, which ensures that each B cell expresses a unique kind of antibody.  
The mechanisms that govern the orderly progression of the V(D)J recombination events, 
including allelic exclusion, remain poorly understood. 
After the successful completion of V(D)J recombination in both heavy and light 
loci, a B-cell receptor is expressed at the cell surface, and the B-cell precursor becomes 
immature B cell [1].  After selection against self-reactivity, the surviving immature B 
cell leaves the bone marrow and migrates to the spleen to become mature B cells, which 
circulate in the peripheral lymphoid tissues to monitor against infectious agents [1].  
 
1.1.2 Gene conversion 
V(D)J recombination is a major contributor of antibody diversity in murine and 
human B cells.  By contrast, a different mechanism is utilized to generate a diverse 
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repertoire of antigen receptors in avian species.  In chicken, the IgH locus contains only 
a single functional V and J gene segment and 16 D gene segments [3], and there is only 
one light chain locus, Igλ, which contains a single functional V and J gene segment (Fig. 
1.2) [3].  Obviously, such a simple Ig gene structure is not sufficient to generate a 
diverse repertoire of antibodies via V(D)J recombination alone.  To compensate, 
chickens have evolved a gene conversion strategy to diversify the antigen-binding site.  
The process involves tandem arrays of pseudo-genes that are positioned upstream of the 
rearranged variable regions in both the IgH and Igλ loci [3] (Fig. 1.2).  During gene 
conversion, random stretches of the pseudo-gene sequences are transferred into the 
rearranged variable regions [4] (Fig. 1.2), and the range of antigen-binding sites are 
substantially expanded as a consequence.  The gene conversion reaction is accompanied 
by non-templated mutations in the variable region, akin to the somatic hypermutation that 
usually takes place during the activation of mature B cells, and such random mutations 
also contribute to the diversification of antigen-binding sites.  Ig gene conversion takes 
place in an organ unique to birds, the bursa of Fabricius.  In chickens, V(D)J 
recombination starts in the B-cell precursors in the yolk sac on embryonic day 5 to 6 and 
ends by embryonic day 15 [5].  These B-cell precursors seed into the bursa of Fabricius 
between embryonic day 10 to 15, where they undergo extensive proliferation and gene 
conversion as well as low levels of somatic hypermutation [5].  The bursa involutes at 
about 4 to 6 months after hatching, and mature B cells migrate to peripheral lymphoid 







Figure 1.2.  Gene conversion at the rearranged Ig Vλ region in chicken B cells.  Structure of the 
rearranged chicken Igλ locus is illustrated.  Twenty five pseudo V gene segments are situated 
upstream of the rearranged variable region.  The arrow indicates the transfer of genetic information 
from the pseudo genes into the rearranged variable region.  Abbreviations: L, leader exon; VJ, 
rearranged variable Ig region composed of joined V and J gene segments.   
 
 
1.1.3 Somatic hypermutation 
Even though V(D)J recombination and gene conversion are effective mechanisms 
of antibody diversification, the resultant antibodies are not specifically directed against 
any particular antigen before the naïve B cells have experienced an immune response.  
For this reason, the antibodies produced by naïve B cells in a primary immune response 
are generally of low affinity toward the offending infectious agents [6].  To remedy this 
deficiency, upon antigenic challenge, B cells undergo a process called somatic 
hypermutation to improve the specificity of the antigen-binding site [1].  This reaction 
takes place within the germinal centers of lymphoid tissues, such as the spleen and lymph 
nodes [1].  The process is characterized with high levels of primarily point mutations 
within the variable regions of both the IgH and L chains.  The mutation rate was 
estimated to be in the range of 10
-3
 per base pair (bp) per cell generation, which is 
approximately a million fold higher relative to the spontaneous mutation rate in the 
L     VJλ                  Cλ  
25 pseudo V genes 
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genome in general [7].  The mutations are distributed in a region that is approximately 
150-bp to 2-kb downstream of the V region transcription initiation site (Fig. 1.3) [7].  
The peak of mutation activity centers on the V region, and the C region is not affected by 
the mutation process (Fig. 1.3) [7].  Within the variable region, these points mutations 
are distributed in a largely random fashion, but those mutations that improve the antigen 
binding affinity are selected, and these B cells undergo further expansion and eventual 
maturation into plasma cells and memory B cells, which are capable of producing 
antibodies of higher affinity relative to those produced by the original naïve B cells [1].  
This process is called affinity maturation, and underlies the increased potency of humoral 






Figure 1.3.  The somatic hypermutation at the human rearranged IgH locus.  * represents somatic 
hypermutations.  The curve above the rearranged IgH variable region (VDJ) depicts the mutation 
region and frequency.  Somatic hypermutation is primarily confined to a region that is between 150-
bp to 2-kb downstream of the transcription initiation site of the V region promoter, which is indicated 
with an arrow. 
 
 
VDJ Cµ Cα2 
* * *** ***** ** * **  * *  **  
*  *  *   *  
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1.1.4 Class switch recombination 
Antibody class and effector functions are determined by the isotypes of Ig heavy 
chain constant regions (CH) [1].  There are five major isotypes of IgH: µ, δ, γ, α, and ε in 
human and mice, with subtypes within the γ and α families [1].  Each heavy chain 
isotype is encoded by a distinct CH gene downstream of the rearranged VH region at the 
IgH locus (Fig. 1.4) [1].  In naïve B cells, Cµ is the constant region gene that is most 
proximal to the rearranged VH gene (Fig. 1.4).  For this reason, Cµ is expressed in 
association with VH through transcription and splicing to form IgM (Fig. 1.4) [1].  When 
naïve B cells are stimulated by antigen within peripheral lymphoid tissues, such as the 
spleen or lymph nodes, Ig heavy chain constant region is triggered to undergo class 
switch recombination (CSR) [1].  This recombination reaction takes place between 
switch (S) regions that precede each CH gene except Cδ (Fig. 1.4) [1, 8].  During CSR, 
two S regions are cleaved and joined together, and the intervening sequence is excised as 
an extra-chromosomal circle (Fig. 1.4) [1, 8, 9].  As a consequence, Cµ is replaced with a 
downstream CH exon, and the IgH isotype is switched to a different class (Fig. 1.4) [1, 8, 
9].  Since different CH regions elicit distinct immune responses, class switch 
recombination diversifies the effector functions of antibodies, and allows the production 






Figure 1.4.  Class switch recombination at the human IgH locus.  Human CH region structure is 
illustrated (not to scale).  In this diagram, B cells are stimulated to undergo class switching to Cε.  
 
 
In summary, four pathways contribute to the diversity of antibodies.  In mice and 
humans, V(D)J recombination is responsible for generating the primary repertoire of 
antigen-binding sites during the early stages of B cell maturation in the bone marrow.  
By contrast, a different strategy has evolved in avian species to develop the primary pool 
of antigen receptors.  In chickens, Ig gene conversion, rather than V(D)J recombination, 
VDJ iE Cµ Cα2 3’RR Cδ Cγ3 Cγ1 ψCε Cα1 Cγ2 Cε Cγ4 
VDJ Cµ 
VDJ Cµ Cε 
VDJ Cε 
VDJ Cε 
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is the major contributor to Ig diversity during B-cell development in a unique avian 
organ, the bursa of Fabricius.  After B cells have matured and migrated to the peripheral 
lymphoid tissues, their antigen specificity could undergo further modification during an 
immune response.  Upon antigenic challenge, the variable regions of activated B cells 
accumulate somatic hypermutations, which improve the antigen-binding affinity of the 
antibodies.  In addition, activated B cells undergo class switch recombination to expand 
the range of effector functions elicited by the antibodies, which facilitates the elimination 
of the infectious agents.  Mechanistically, V(D)J recombination is mediated by the 
RAG-1 and RAG-2 recombinase, whereas the remaining three pathways, gene 
conversion, somatic hypermutation and class switch recombination, involve a distinct 
factor, Activation Induced Cytidine Deaminase (AID), which is introduced in the 
following section. 
 
1.2 ACTIVATION-INDUCED CYTIDINE DEAMINASE MEDIATES CLASS SWITCH 
RECOMBINATION, SOMATIC HYPERMUTATION AND IG GENE CONVERSION. 
AID was originally identified in activated B cells [10].  Its role in class switch 
recombination, somatic hypermutation, and Ig gene conversion was established by 
genetic evidence in mice, chicken B-cell lines as well as in humans [11].  Ablation of 
the AID gene in mice completely inhibits class switch recombination and somatic 
hypermutation [12].  A similar phenotype was observed in human patients who have 
inherited defective copies of the AID gene [13].  These patients suffer from an immune 
deficiency called hyper IgM syndrome, which is characterized with abnormally low 
levels of IgG and IgA in the blood due to defective class switch recombination in B cells, 
and the variable regions of their immunoglobulin genes lack somatic hypermutations 
[13].  Because of these defects, these patients are prone to develop recurrent infections 
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at an early age [13], clearly demonstrating the importance of AID and the two AID-
dependent pathways, class switch recombination and somatic hypermutation, in effective 
immunity.  In chicken B cells, ablation of the AID gene abolishes Ig gene conversion 
[14], establishing a mechanistic link between this pathway with the apparently distinct 
class switch recombination and somatic hypermutation. 
Based on sequence homology, AID belongs to the family of cytidine deaminases 
and is most closely related to the family member, apolipoprotein B mRNA-editing 
enzyme, catalytic polypeptide 1 (APOBEC-1).  The function of APOBEC-1 has been 
well established: the enzyme deaminates C2153 of apoB100 mRNA to U2153 [10].  The 
editing creates an in-frame stop codon, which leads to the production of a truncated 
protein with novel functions [10].  Based on this information, the RNA editing model 
was proposed by Honjo’s group to explain the function of AID (Fig. 1.5) [15].  
According to this model, AID was hypothesized to edit a putative pre-mRNA to allow the 
expression of a protein that is involved in class switch recombination, somatic 
hypermutation and Ig gene conversion; for example, the putative editing target of AID 
could be an endonuclease that cleaves the switch regions during class switch 
recombination.  In spite of the apparent analogy between AID and APOBEC-1, no RNA 




Figure 1.5.  The RNA-editing model of AID. 
 
 
Due to the lack of concrete evidence for the RNA editing hypothesis, an 
alternative model was proposed to explain the function of AID (Fig. 1.6) [11, 16].  In 
this model, the substrate of AID is DNA rather than RNA, and the cytidine deamination 
activity of AID leads to the accumulation of uridines in target DNA within the Ig loci  
[11, 16].  With respect to class switch recombination, the target DNA would be the 
switch regions, and AID is thought to deaminate cytidines within switch region DNA [8].  
AAAAAAA C AAAAAAA U 
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The resultant uridines could be removed by the uracil DNA glycosylase, and the abasic 
sites would be cleaved by AP endonuclease to form single-stranded nicks [8].  The 
deamination reaction could also activate the mismatch repair system, which recognizes 
U:G mismatches, and could potentially introduce DNA strand breaks in the process of 
removing the mismatch [17].  If the reaction occurs at high frequency in the switch 
region, two nicks could be formed in close proximity on both strands and result in a 
double stranded DNA break; ligation of the double-stranded DNA breaks in two switch 
regions would lead to class switch recombination [8].   
The DNA deamination model could also be applied to explain somatic 
hypermutation and Ig gene conversion; in this case, the DNA target of AID would be the 
Ig variable region [7]; AID would deaminate cytidines in the Ig variable region DNA, 
and the downstream processing of the resultant uridines by different pathways could give 
rise to either somatic hypermutation or gene conversion.  For example, replication of a 
DNA template containing the uridines would result in C:G to T:A transitions in the 
daughter DNA strands [16, 18, 19].  If the uridines have been removed by uracil DNA 
glycosylase before DNA replication, abasic sites would accumulate in the DNA and 
interfere with the progression of the normal replication DNA polymerase through the 
template [16, 18, 19].  To rescue the stalled DNA replication process, the cells would 
resort to error-prone DNA polymerases that are capable of translesion synthesis through 
abasic sites, with the price that incorrect nucleotides would be incorporated in opposition 
to the abasic sites in the daughter DNA strand, leading to either transition or transversion 
type of mutations [16, 18, 19].   
Additionally, the U:G mismatch could also be the target of mismatch repair 
system as described earlier [17].  To correct the mismatch, the mismatch repair system 
normally excises a stretch of DNA containing the mismatch, and the resultant gap could 
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potentially be filled in by error-prone DNA polymerases to introduce mutations.  Ig 
gene conversion could be accomplished through a similar pathway up to the stage of 
abasic site formation in the Ig variable region [20].  In the case of gene conversion, 
these abasic sites would be cleaved by the AP endonuclease to form DNA strand breaks, 
which could be repaired by the homologous recombination machinery, using the adjacent 






Figure 1.6.  The DNA-editing model of AID.  Abbreviations: UNG: uracil DNA glycosylase; APE: 




The DNA deamination model is consistent with several experimental 
observations.  A key prediction of the DNA deamination model is that uracil DNA 
glycosylase would play an important role in AID-mediated Ig diversification events.  
Consistent with this prediction, genetic ablation of uracil DNA glycosylase gene in mice 
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leads to severe reductions in class switch recombination, and alters the pattern of somatic 
hypermutation [22].  Similarly, human patients with defects in the uracil DNA 
glycosylase gene exhibit symptoms of hyper-IgM syndrome with reduced levels of IgG 
and IgA in the serum, which is indicative of defects in class switch recombination [23].  
Inactivation of the uracil DNA glycosylase gene in chicken B cells also compromises Ig 
gene conversion [24].  Besides uracil DNA glycosylase, the mismatch repair system and 
error-prone DNA polymerases have also been implicated in the processing of AID-
induced Ig diversification events, and examination of animals deficient in these repair 
factors also yields results that are consistent with the prediction of the DNA deamination 
model [25].  Consistent with these genetic analyses, biochemical studies showed that 
AID is indeed capable of deaminating cytidines in the context of DNA in vitro [26-36]. 
In summary, AID has been established as the key factor for three apparently 
distinct pathways of Ig diversification: class switch recombination, somatic 
hypermutation and Ig gene conversion.  Most of the current experimental evidence 
supports the model that AID functions by deaminating cytidines in target DNA: switch 
regions and variable regions at the Ig loci.  Subsequent processing of the deamination 
product, uridine, via different repair pathways could result in class switch recombination, 
somatic hypermutation and gene conversion. 
  
1.3 AID FUNCTION IS REGULATED AT MULTIPLE LEVELS. 
Although the DNA deamination model could satisfactorily explain some of the 
key observations of AID function, it raises an important question: how is the DNA 
deamination activity of AID localized to the physiological targets in the Ig loci, that is, 
the switch regions and variable regions?  The question is important since indiscriminate 
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deamination of the whole genome would lead to rampant mutations and genomic 
instability.  For this reason, AID function is under stringent regulation at multiple levels.  
The following is a discussion of these regulatory mechanisms. 
 
1.3.1 Transcriptional regulation of AID 
AID expression is restricted to activated B cells [10] and bursal B cells [14], 
where AID function is needed for Ig diversification.  The importance of this level of 
control is demonstrated by experiments where AID is expressed with a ubiquitous 
promoter in transgenic mice [37].  The ectopic expression of AID leads to the 
development of T-cell lymphomas as well as tumors in other tissues, such as the lung 
[37].  The transcriptional regulation of AID has been most extensively analyzed in mice.  
It has been shown that the induction of AID expression during B-cell activation involves 
several transcription factors, including Pax5, STAT6, NF-κB, IRF4, IRF8, and HoxC4 
[38-43].  However, the mechanism responsible for AID expression in chicken bursal B 
cells is poorly understood.  Since there is little sequence homology between the chicken 
and mouse AID promoters, the regulatory mechanism may differ between the two 
species.  It has been shown that ablation of Pax5 reduces AID expression in the chicken 
bursal B cell line DT40 [44].  Since loss of Pax5 induces plasma cell differentiation, it is 
unclear whether Pax5 directly regulates the AID gene. 
 
1.3.2 Post-transcriptional regulation of AID 
Besides transcriptional regulation, AID expression is also subject to controls at 
various posttranscriptional levels.  The stability of AID mRNA has been shown to be 
negatively regulated by microRNAs, miR-181b [45] and miR-155 [46, 47], which 
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recognize elements in the 3’ untranslated region of the AID transcript.  Additionally,  
AID protein shuttles between the nucleus and cytoplasm, and this shuttling is controlled 
by a nuclear localization signal in the N-terminus and a nuclear export signal in the C-
terminus of the polypeptide [48].  During the steady state, most of the AID protein is 
localized in the cytoplasm [49, 50], which would reduce the potential for nonspecific 
deamination in the genome.  The predominant cytoplasmic location of AID appears to 
be the consequence of at least two factors: the relative strength of export versus import 
signal [49, 50] and the preferential degradation of the nuclear form of AID [51]. 
 
1.3.3 Recruitment of AID to the physiological targets at the Ig locus   
The regulation of AID levels by both the transcriptional and posttranscriptional 
mechanisms is unlikely to be sufficient to prevent genomic instability, since AID is still 
expressed in B cells at levels sufficient to induce mutation in the Ig loci.  The question is 
how AID is targeted to the physiological targets at the Ig loci within B cells.  The targets 
of AID during class switch recombination are the switch regions, which are composed of 
1-10 kb of repetitive DNA [8].  The sequences of switch regions are characterized with 
two unusual features: the non-template strand is G-rich and there are abundant AGCT 
motifs in the repetitive DNA [8].  As described earlier, class switch recombination is 
closely linked with transcription from promoters situated upstream of the switch regions 
[8].  The transcription through the switch regions generates a non-coding RNA, which is 
G-rich due to the high C content in the template strand of the switch region DNA [8].  It 
has been shown that the G-rich RNA tends to associate with the template DNA to form 
an RNA-DNA hybrid and displaces the non-template strand as single-stranded DNA; this 
structure is called an R-loop [52].  Such R-loops have indeed been detected in vivo in 
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the switch regions engaged in class switch recombination [52-55].  Moreover, genetic 
experiments showed that inhibiting R-loop formation in switch regions reduces the 
efficiency of class switch recombination in mice [53].  The role of R-loop could be 
explained by the substrate requirement of AID.  AID can only deaminate cytidines in 
the context of single-stranded DNA, since the amino group in cytidine is engaged in 
hydrogen bonding with the complementary base in double-stranded DNA.  The 
displaced non-template strands in an R-loop have been shown to be good substrates for 
AID in vitro [27, 28, 30, 31], which would be consistent with a role of this structure 
during class switch recombination.  The second feature of switch regions is the large 
number of AGCT motifs in the repetitive DNA [8].  It has been shown that the AGCT 
motif represents a hotspot for the AID deamination activity in vitro [56, 57].  Thus, the 
combination of R-loop formation and high densities of AGCT motif could render the 
switch regions prime targets for AID function.  Besides the unusual nature of switch 
region sequence, other mechanisms, such as the recruitment of AID to the Ig loci via 
transcription factors, could also be involved, and these mechanisms are discussed in more 
detail below. 
The targeting mechanisms for AID during class switch recombination cannot be 
readily applied to explain the targeting of AID to the Ig variable regions in somatic 
hypermutation and gene conversion.  In contrast to the unusual sequence of the switch 
regions, the Ig variable region does not show any distinctive features relative to DNAs in 
non-Ig loci.  In fact, non-Ig DNAs could become targets of AID when incorporated into 
the Ig loci [58].  Therefore, elements outside of the variable region are likely recruiting 
AID to the target.  The prime candidate for the recruiting elements is the transcription 
apparatus of the Ig loci.  Similar to class switch recombination, transcription is a 
prerequisite to both somatic hypermutation and Ig gene conversion [59-61].  Moreover, 
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the spatial distribution of somatic hypermutation is determined by the relative distance to 
the promoter: the mutations are confined to a region that is 150 bp to 2 kb downstream of 
the transcription initiation site [7].   
In spite of the correlation, transcription per se cannot be sufficient to target AID 
function, since many highly transcribed non-Ig genes in B cells are not mutated by AID 
[62].  A potential explanation is that the transcription apparatus at the Ig genes is 
somehow different from the other genes.  This reasoning has prompted extensive 
analyses of the Ig promoters and enhancers.  It was found that non-Ig promoters could 
function in place of the Ig promoter in both somatic hypermutation [63, 64] and gene 
conversion [65].  Therefore, the Ig promoter is generally not considered to be the 
determinant for AID target specificity, although exceptions have been observed in one 
study [66].   
The main focus for AID targeting is currently on the Ig enhancer elements.  In 
mice, several Ig enhancers have been identified in the Ig loci [2].  These enhancers 
appear to have overlapping functions, since deletion of individual enhancers at the 
endogenous Ig loci did not appear to have a major impact on somatic hypermutation [67-
70].  Similar analyses have been performed at the chicken Igλ locus in the chicken B-
cell line DT40 [65, 71, 72].  The consensus from these studies is that multiple regulatory 
elements downstream of the Igλ constant region contribute to the targeting of AID to the 
locus.  In particular, a 2.4-kb region (Region A) appears to have a more prominent role 
in this process, since deletion of this region results in severe reductions in AID-mediated 
gene conversion [65].  More importantly, the 2.4-kb region is capable of targeting AID 
function to ectopic sites outside of the Ig genes [65].  It remains to be established how 
this regulatory element facilitates AID function.   
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The complementary approach to the dissection of cis-acting elements is to 
identify the trans-acting factors that recruit AID to target DNA.  So far, the only protein 
that has been shown to interact with AID is replication protein A (RPA) [36], a protein 
that binds single-stranded DNA, and is involved in both DNA replication and repair.  
RPA has been shown to stimulate AID mediated deamination of DNA in a transcription 
dependent manner in vitro [36].  The observation could be explained by the stabilization 
of transient unwound DNA strands during transcription, which would become substrates 
for AID.  Although the finding could explain how AID gains access to cytidines in 
transcribed DNA, it is not sufficient to explain why AID is targeted to the Ig loci since 
RPA interacts with single-stranded DNA in a largely sequence non-specific manner.  
RPA has been shown to associate with switch regions during class switch recombination 
[73], but no specific interaction of RPA with the Ig variable region during somatic 
hypermutation or gene conversion has been reported.  Thus, there must be other factors 
that could target AID function specifically to the Ig loci.   
The transcription factor, E2A, may represent one such AID-targeting factor.  
E2A has been implicated in the function of enhancers at the Ig locus [74-77].  
Importantly, ablation of E2A gene in chicken B cells leads to severe reductions in Ig gene 
conversion [78], whereas introduction of extra copies of the E2A-binding site, the E box, 
into the Ig variable region stimulates the levels of somatic hypermutation in mice [76].  
Nonetheless, it remains to be demonstrated whether E2A indeed recruits AID to the Ig 
locus through direct association.  Furthermore, the E2A-binding site, E box, is defined 
by a short consensus: CANNTG, which can be found in many places in the genome and 
is therefore unlikely to be sufficient to specify AID targets.  If E2A indeed functions to 
target AID to the Ig locus, it most likely does so in collaboration with other factors, but 
the identities of such factors remain to be established.   
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In this regard, recent studies have implicated the NF-κB family of transcription 
factors in AID function, since inactivation of two NF-κB family members, p50 and c-Rel, 
impairs AID-mediated gene conversion [65].  At present, it is unclear whether the NF-
κB proteins collaborate with E2A.  Thus, the mechanisms that target AID to the Ig 
variable regions remain an open question. 
 
1.3.4 Differential repair of AID mediated mutations in Ig versus non-Ig loci 
Although AID activity is primarily targeted to the Ig loci, certain non-Ig loci do 
sustain mutations in activated B cells, albeit at levels substantially lower (at least a 
magnitude) relative to somatic hypermutation at the Ig loci [79-82].  These mutations in 
non-Ig genes bear the hallmark of AID-mediated somatic hypermutation: they are 
primarily localized to the promoter-proximal region and exhibit preference for AID 
mutation hotspots such as the RGYW motif (R=A,G; Y=C,T; W=A,T) [79-82].  
Although these non-physiological targets are non-Ig genes, some of them do share certain 
characteristics with the Ig genes.  For example, the genes encoding Bcl6, CD79A and 
CD79B genes are all highly expressed in activated B cells, and may share common 
transcription machinery with the Ig genes, which could explain the targeting of AID to 
these loci.  At present, it is not clear why these genes would become mutation targets of 
AID in normal B cells.  In fact, mutation of Bcl6 is frequently associated with the 
development of B-cell lymphomas in humans.  It is not clear why B cells have not 
evolved a mechanism to prevent the accumulation of mutations in the Bcl6 gene.  
A recent study has comprehensively examined the mutation levels of a large 
number of non-Ig genes in activated B cells, and found that AID-mediated mutations are 
more widespread than previously thought [83].  In addition to the previously identified 
non-Ig targets, such as Bcl6, many more non-Ig genes in fact sustain a low level of AID-
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mediated mutations during B-cell activation [83].  The mutation load of non-Ig genes 
becomes even higher in B cells that are deficient in the uracil DNA glycosylase and the 
mismatch repair system [83].  The observation suggests that the targeting of AID to the 
Ig loci is not complete, and AID does have access to other parts of the genome.   
Most of the mutations outside of the Ig loci are normally eliminated by high 
fidelity repair.  If this is true, why doesn’t high fidelity repair prevent the accumulation 
of somatic hypermutation at the Ig loci?  It is possible that, due to the preferential 
targeting of AID to the Ig loci, the high mutation loads at the Ig loci have overwhelmed 
the capacity of high fidelity repair.  Alternatively, it is possible that the repair process at 
the Ig loci is corrupted in a way to favor the error prone pathway of mutation processing.  
Thus, the apparent mutation specificity in the Ig loci could also be a consequence of 
differential repair relative to non-Ig loci, and the above mentioned cis-acting elements 
and trans-acting factors could contribute to this mechanism of regulation as well.  For 
example, a factor could recruit an error-prone repair enzyme instead of AID. 
In summary, the mutagenic activity of AID needs to be under stringent control to 
prevent deleterious mutations in the genome in general.  The control may involve 
multiple mechanisms, which include: the B-cell-specific expression of AID; regulation of 
AID mRNA stability by micro-RNAs; reduction of the nuclear concentration of AID by 
preferential export into the cytoplasm and degradation of the nuclear fraction of AID; 
recruitment of AID to the Ig loci; and error-prone repair of AID-induced lesions at the Ig 
loci.  Many of these proposed regulatory mechanisms are not fully understood, and the 
study presented in this dissertation is designed to address this issue.   
Specifically, I present evidence that two lymphoid specific transcription factors, 
PU.1 and IRF4, regulate AID function at two levels.  I show that PU.1 is a major 
positive regulator of AID expression in chicken B cells, and this regulation appears to 
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involve direct interaction of PU.1 with the AID gene.  Moreover, the dosage of PU.1 is 
critical for AID function, since a severe reduction in AID mediated gene conversion was 
observed in PU.1
+/-
 cells, even though AID expression is normal in this situation.  IRF4 
is a functional partner of PU.1, and the two proteins can form a complex to interact with a 
combined Ets-IRF binding site.  The connection led me to examine the role of IRF4 in 
the regulation of AID as well.  I found that IRF4 plays a minor role in AID expression, 
but is important for AID-mediated gene conversion at the Igλ locus, and the function of 
IRF4 appears to involve two binding sites within a regulatory element in the Igλ locus.  
Thus, my study shows that PU.1 and IRF4 are important regulators of AID function in 
chicken B cells.  
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Chapter 2  
Materials and Methods 
2.1 CELL CULTURE AND TRANSFECTION 
All the experiments in this study were performed in DT40 cells and its 
derivatives.  The cells were maintained in RPMI media supplemented with 10% fetal 
bovine serum, 1% chicken serum, 27µM β-mercaptoethanol, 100 units/ml penicillin, and 
100µg/ml streptomycin.  For transfection, 10µg of linearized plasmid was electroporated 
(600V, 25µF) into 1x10
7
 cells.  Drug selection was started a day after the transfection.  
For puromycin resistance, the drug was added to a final concentration of 0.5µg/ml.  For 
gpt selection, mycophenolate was used at a concentration of 5µg/ml.  The colonies from 
the transfection were analyzed by Southern blotting to identify the desired targeting 
events.  In all the targeting experiments, the drug selection marker was subsequently 
removed through Cre-mediated recombination via flanking loxP sites.  The Cre 
recombinase is expressed from a stably integrated transgene in the DT40 cell line, and its 
activity is inducible with tamoxifen [84].  For Cre-mediated excision of the drug 
selection marker, the cells were treated with 25nM of 4-hydroxy-tamoxifen for a day.  
Afterwards, single colonies were isolated through subcloning, and removal of the drug 
selection marker was confirmed with Southern analysis of the clones.  In some 
experiments, the conditions for transfection and tamoxifen treatment were adjusted from 
the general protocol to fit the conditions of particular cell lines and reagents.   
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2.2 TARGETED MUTAGENESIS 
This section describes the location of deletions described in this study.  To 
specify the locations of the various deletions, the transcription initiation site is designated 
as position +1, and its sequence context is provided for reference.  For the PU.1 gene, 
the sequence surrounding the transcription initiation site is CTCAGA
+1
ACCT.  The first 
and second targeting construct deletes the regions from -3655 to +750 and -187 to +750, 
respectively.  For the IRF4 gene, the sequence surrounding the transcription initiation 
site of is TGACGG
+1
AGAG.  The first and second targeting construct deletes the 
regions from +620 to +3439 and +2837 to +3439, respectively.  For the AID gene, the 
sequence around the transcription initiation site is ACAGAG
+1
CATT.  The PU.1-IRF4 
composite binding site is from positions +305 to +315.  In AID
+/∆
 cells, the inactive 
allele contains a deletion from +2743 to +3502.  For the Igλ gene, the sequence context 
of the transcription initiation site is CCATCG
+1
GCGT.  For the rearranged Igλ allele, 
the composite PU.1-IRF binding sites, the two PU.1-IRF4 composite binding sites are 
located from +4015 to +4025 and from +5412 to +5421, respectively.  The region B 
deletion is from +6,450 to +14,124.  Since this study involves a large number of 
targeting events, details of the constructs are omitted.  The information is available upon 
request.   
 
2.3 GENE CONVERSION ASSAY 
The gene conversion reporter was generated by inserting an I-SceI recognition 
sequence into the SalI site of the puromycin resistance gene (puro): GTC Ggc tag gga 
taa cag ggt aat gcA CCC (the inserted sequences are in lower case letters and the I-SceI 
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recognition sequence is in bold).  A fragment of puro serves as the donor in gene 
conversion; if the A of the start codon is designated as position +1, the fragment 
corresponds to +1 to +333 of the open reading frame.  The puro fragment is positioned 
approximately 2-kb upstream of the promoter.  The reporter is transcribed with the 
chicken Igλ promoter, which contains sequences from -1,363 to +25.  The gene 
conversion substrate was integrated at position +4,007 of the rearranged Igλ locus.  
For gene conversion experiments, the cells were subcloned by serial dilution in 
96-well tissue culture plates.  The day of subcloning was day 0.  After 9 days, single 
colonies were transferred into 24-well tissue culture plates and cultured for 3 more days.  
At day 12, a portion of the cells was transferred into 12ml media containing 0.5µg/ml 
puromycin, while another aliquot of the cells was diluted into 12ml media without 
puromycin.  The cell numbers used in each experiment are shown in the Supplementary 
Tables 1 through 3.  Each 12ml of cells was distributed into a 96-well tissue culture 
plate.  Colonies were counted under a microscope 6 to 7 days later. 
 
2.4 DAM METHYLASTION ASSAY 
The Dam methyltransferase cDNA was derived from E. coli.  As explained in 
the text, a point mutation, R95A, was introduced into the gene to reduce the DNA-
binding affinity of the Dam protein.  The Dam gene or its fusion with PU.1 or IRF4 was 
expressed with a tamoxifen-inducible construct, which was stably integrated into the 
genome of DT40 cells.  As described in detail in the text, Dam expression was induced 
in the presence of 25nM 4-hydroxy-tamoxifen.  Genomic DNAs were isolated from 
cells after 24 or 48 hours of tamoxifen treatment, and analyzed by Southern blotting. 
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2.5 I-SCEI MEDIATED GENE CONVERSION ASSAY 
The I-SceI expression construct was integrated into the AID locus of either wild-
type or IRF
-/-/-
 cells that contained the gene conversion substrate.  The integration sites 
are between +2404 and +3502.  The deletion eliminates exons 2 through 4 of the AID 
gene.  The other allele of AID gene was inactivated by deletion from +2743 to +3502, 
which contains exons 3 and 4.  I-SceI expression was induced with 25nM 4-hydroxy-
tamoxifen for one day, and the cells were subcloned by serial dilution in 96-well tissue 
culture plates for gene conversion analysis as described in the previous section. 
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Chapter 3  
PU.1 and IRF4 regulate AID gene expression. 
3.1 BACKGROUND 
Based on sequence homology, PU.1 belongs to the family of Ets domain-
containing transcription factors, and is mainly expressed in hematopoietic lineage cells 
[85].  The Ets domain of PU.1 is responsible for its DNA-binding ability and recognizes 
a DNA sequence with the core GGAA motif [86-88]; in fact, it was originally isolated as 
binding factor for a purine-rich motif in the murine MHC class II 1-Ab gene promoter 
[89].  Based on genetic studies in mice, PU.1 regulates the expression of genes that are 
important for the development of both myeloid and lymphoid lineage cells [85, 90].  For 
example, PU.1 has been shown to interact with the Il-7rα gene promoter and to up-
regulate the expression of IL-7 receptor, which is critical for the survival and 
proliferation of both B and T-cell precursors [91].   
Because of the critical role of PU.1 in the early stage of lymphoid developments, 
mice deficient in PU.1 completely lack both B and T cells [92-94], and the role of PU.1 
in mature B cells was addressed by the approach of conditional ablation of PU.1 in B 
cells [95].  The inactivation of PU.1 in the mature B cell stage had only minor effects on 
B-cell number in the peripheral lymphoid tissues [95].  In addition, B cells deficient in 
PU.1 undergo class switch recombination normally in response to antigenic challenge, 
and the affinity maturation of antibodies, a reflection of somatic hypermutation, is also 
unaffected [95].  These observations suggest that PU.1 is largely dispensable at the 
mature stage of B cell in mice.  Similarly, no obvious phenotype was reported when the 
PU.1 gene was disrupted in a chicken B-cell line DT40 [96], although, in this case, a 
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truncated PU.1 protein was detected in the cell lysate and residual DNA-binding activity 
for a PU.1 consensus binding site was still detectable in electrophoresis mobility shift 
assays (EMSAs); the impact of the mutation on Ig gene conversion was also not 
examined.  In spite of the apparent dispensability, PU.1 remains highly expressed in 
mature B cells [97, 98], and binding sites for PU.1 have been found in the enhancers of 
both Ig heavy and light chain loci in mice [90].  Therefore, it remains possible that PU.1 
has a role in later stages of B-cell development, but its function is masked by redundant 
factors.  Indeed, among the Ets family members, PU.1 is closely related to Spi-B, which 
is also expressed in B cells, especially in the more mature stages of B-cell development 
[99].  It is therefore possible that Spi-B is capable of compensating for the loss of PU.1 
in the mature B-cell stage. 
The transcription factor, Interferon Regulatory Factor 4 (IRF4), is a functional 
partner of PU.1 [100-103].  IRF4 is a lymphoid-specific member of the interferon 
regulatory factor (IRF) family, which is characterized by a helix-turn-helix type of DNA-
binding motif at the N-terminus of the polypeptide [104].  PU.1 and IRF4 can form a 
heterodimeric complex and interact with a combined Ets-IRF binding site, which is 
composed of the recognition motifs for both PU.1 (GGAA) and IRF4 (GAAA) with a 
spacing of 2 to 3 bp [105].  Although PU.1 is capable of binding independently to the 
Ets-IRF motif, its association is enhanced in the presence of IRF4 [102].  On the other 
hand, IRF4 shows very weak DNA-binding activity by itself, and generally requires 
collaboration with PU.1 [100] or other factors, such as E2A [106], for effective 
interaction with DNA.  The synergy between PU.1 and IRF4 is beyond DNA binding, 
and is exhibited at the level of transcriptional activation as well, as demonstrated in 
transfection studies [100].   
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IRF4 is expressed throughout B-cell development as well as in mature T cells 
[107].  Unlike other members of the IRF family, IRF4 is induced by B-cell receptor 
stimulation, but not by viral infection, suggesting a function independent of interferon 
induction [107].  Genetic studies indicate that IRF4 is crucial for the maturation and 
function of B cells [108].  In IRF4-deficient mice, the early B-cell development is 
normal, but B-cell maturation and function in the peripheral lymphoid tissues are 
impaired [108].  The IRF4-deficient mice have severely reduced levels of 
immunoglobulin in the serum; IRF4-deficient B cells do not respond properly to antigen 
stimulation and fail to proliferate and secrete antibodies [108].  Due to the maturation 
defect of B cells, it is not feasible to determine the potential role of IRF4 in class 
switching and somatic hypermutation in these mice.   
To circumvent this problem, Klein and colleagues used a conditional knockout 
strategy to ablate the IRF4 gene during B-cell activation, and found a defect in class 
switch recombination in IRF4-deficient B cells [41].  Furthermore, they showed that 
AID expression is reduced in IRF4-deficient B cells, which can explain the defect in class 
switching [41].  A similar conclusion was reached in another study [40].  Thus, IRF4 
appears to be a positive regulator of AID expression.  It remains to be determined 
whether IRF4 directly activates AID gene transcription.   
My interest in PU.1 and IRF4 stems from the presence of a consensus Ets-IRF 
combined binding site in an enhancer element at the chicken Igλ locus.  This Ets-IRF 
binding site is interspersed with putative binding sites for other transcription factors 
implicated in Ig enhancer function such as NF-κB, E2A, as well as Mef2, and, more 
importantly, the arrangement of these binding sites is conserved among chicken, mouse 
and human Igλ enhancers, suggesting a functional relevance.  This observation, coupled 
with information from studies in mice implicating PU.1 and IRF4 in various stages of B-
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cell development and function, prompted me to examine the roles of these two factors in 
AID-mediated gene conversion in chicken B cells.  Toward this end, I inactivated the 
PU.1 and IRF4 genes in the chicken B cell line DT40 and analyzed the effects of the 
mutation on AID function.   
 
3.2 RESULTS 
3.2.1 PU.1 is important for AID expression in chicken B cells. 
My study was performed in the chicken B-cell line DT40, which was derived 
from virally transformed bursal B cells [109].  The cell line maintains AID-mediated Ig 
gene conversion in culture [110, 111].  A key advantage of this cell line is that 
homologous recombination is very efficient, which enables genetic manipulation of the 
genome in homologous targeting experiments [112].  Taking advantage of this property, 
we knocked out the PU.1 gene in DT40 cells to evaluate the role of PU.1 in AID 
function.  To inactivate the PU.1 gene, we deleted the first exon together with the 
upstream promoter region (Fig 3.1A).  Two different targeting constructs were used to 
inactivate the two alleles of PU.1 gene (Fig 3.1A).  The strategy is based on our 
experience that the second targeting event tends to take place on the first targeted allele if 
the same targeting construct is used.  In our approach, one of the homology arms of the 
second targeting construct is within the deleted region of the first targeted allele.  
Therefore, the second targeting event is limited to the remaining wild-type allele.   
Using this method, we mutated both alleles of the PU.1 gene, and no PU.1 mRNA 
is detectable in the homozygous knockout cell line (Fig 3.1B).  PU.1-deficient cells 
grow slower than wild-type cells (data not shown), presumably because certain PU.1 
target genes are involved in cell proliferation.  AID expression was examined in PU.1 
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deficient cells, and found an approximately 10-fold reduction in AID mRNA levels (Fig 
3.1C,D).  This result shows that PU.1 is important for AID expression in DT40 cells.    
 
 
Figure 3.1.  AID expression is strongly reduced in PU.1-deficient cells.  A. This diagram illustrates 
the strategy for inactivating the PU.1 gene.  The exon-intron organization of the PU.1 gene is drawn 
to scale, and the exon numbers are shown.  The deleted region is shown for the targeted alleles, but 
details of the targeting constructs are omitted.  The drug-selection marker was removed after each 
targeting event, and a loxP site was left in place of the deleted region.  B. PU.1 mRNA levels were 
analyzed with Northern blotting.  Each genotype is represented with three samples.  The top 
autoradiograph was hybridized with a PU.1 cDNA probe.  In the bottom autoradiograph, the 
membrane was rehybridized with an EF-1α cDNA probe to normalize RNA loading.  C. AID mRNA 
levels were analyzed by Northern blotting.  Except for AID
-/-
 cells, each genotype is represented with 
three samples.  WT is wild-type cells.  The top autoradiography was hybridized with an AID cDNA 
probe.  In the bottom autoradiograph, the membrane was rehybridized with an EF-1α cDNA probe to 
normalize for RNA loading.  D. The histogram is the quantification of AID mRNA levels as 
analyzed by Northern blotting in C.  The value for each genotype is derived from three samples, and 
the error bar represents standard deviation.  The value for wild-type cells is set as 1, whereas AID
-/-
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3.2.2 IRF4 plays a minor role in AID expression in chicken B cells. 
Since IRF4 is a functional partner of PU.1, it is conceivable that loss of IRF4 
would have a similar impact on AID expression.  To test this hypothesis, we also 
inactivated the IRF4 gene in DT40 cells.  This experiment is complicated by the fact 
that the gene resides on chromosome 2, which is present in three copies in DT40 cells.  
For this reason, we performed three rounds of targeting with two different constructs 
(Fig. 3.2A).  The first targeting construct deletes exons 2 through 5, which include the 
translation start codon and encode the DNA-binding domain.  Moreover, splicing of 
exon 1 to exon 6 leads to a frame-shift mutation.  For the second and third alleles, the 
construct deletes part of exon 5 together with the splice donor at the 3’ end of the exon.  
Under this situation, exon 4 could potentially be spliced to exon 6, which generates a 
frame-shift mutation in exon 6.   
Using this strategy, we have targeted all three alleles of the IRF4 gene in DT40 
cells.  In IRF4
-/-/-
 cells, residual IRF4 mRNA is detectable with Northern analysis, and 
may correspond to the truncated transcripts from the targeted alleles (Fig. 3.2B).  Since 
exon 5 is 143-bp, the truncated transcript is practically indistinguishable from the wild-
type mRNA on Northern blots.  To ascertain the nature of this transcript, we performed 
RT-PCR with primers that amplify the complete open reading frame of IRF4.  
Sequencing of the RT-PCR products confirmed the expected loss of exon 5 and the 
splicing of exon 4 to exon 6 (data not shown).  This transcript could potentially encode a 
truncated protein containing residues 1-147 of IRF4, which includes the DNA-binding 
domain, but lacks the transactivation function and could potentially act as a dominant 
negative.  However, the truncated message is present at less than 1/10
th
 the level of 
normal transcripts, presumably due to nonsense-mediated RNA decay.  The small 
amount of truncated protein, if indeed produced, should have no significant impact on the 
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function of partner proteins such as PU.1, and the IRF
-/-/-
 cells appear to be devoid of 
functional IRF4 proteins.  The proliferation of IRF4-deficient cells is slower relative to 
wild-type cells, although the defect is less severe compared to PU.1-deficient cells 
The expression of AID was examined in IRF4-deficient cells, and AID mRNA 
levels were reduced by approximately 40% on average (Fig 3.2C).  AID expression is 
variable among different subclones of IRF4-deficient cells, ranging from 30% to 
approximately 70% of wild-type levels.  The reason for this phenomenon is unclear; one 
potential explanation is that loss of IRF4 renders the chromatin structure of the AID 
promoter unstable.  Thus, relative to the more severe defect in AID expression observed 
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Figure 3.2.  AID expression is reduced in IRF4-deficient cells.  A. The strategy to ablate the IRF4 
gene is illustrated in the same way as for PU.1 (Fig. 3.1A).  B. The mRNA levels of IRF4 and AID 
were analyzed with Northern blotting.  The membrane is sequentially hybridized with IRF4, AID and 
EF-1α cDNA probes, respectively.  Except for AID
-/-
 cells, each genotype is represented with two 
samples.  C. The histogram is the quantification of AID mRNA levels as analyzed by Northern 
blotting in B.  The value for each genotype is derived from at least three samples, and the error bar 
represents standard deviation.  The value for wild-type cells is set as 1, whereas the AID
-/-
 cells 
provide the baseline. 
 
 
3.2.3 Mutation of a PU.1-IRF-binding site in AID gene reduces AID expression. 
PU.1 and IRF4 are capable of interacting cooperatively with the Ets-IRF 
composite element (EICE).  Although the distinct phenotypes of PU.1 and IRF4 
knockouts suggests separate roles of the two factors in regulating AID expression, it 
remains possible that the collaboration of these two factors contribute, at least in part, to 
the regulation of AID expression.  Indeed, a consensus EICE is found in the AID gene 
(Fig. 3.3A), and the element is 350-bp downstream of the transcription initiation site, a 
location consistent with a role in transcriptional regulation.   
To test its function, the EICE was deleted through homologous recombination 
(Fig. 3.3A).  The mutation was introduced into a cell line in which one allele of AID 
gene has been inactivated by the deletion of exon 3 and 4 (AID-∆).  The inactive allele 
produces low levels of a truncated transcript (AID-∆), which is distinguishable from the 
wild-type mRNA (AID-WT) on Northern blots (Fig. 3.3B).  The EICE was mutated on 
the wild-type allele of AID gene (AID
m/∆
), and, relative to AID
+/∆
cells, the mutation 
reduces the level of wild-type AID transcript by approximately 50% (Fig. 3.3B), similar 
to the phenotype of IRF4 knockout.  Variability in AID expression was not observed as 
in IRF4-deficient cells, and the reason for this difference is not clear.  This result 
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suggests that PU.1 and IRF4 complex may function through this binding site, but the 




Figure 3.3.  Mutation of a PU.1-IRF composite binding site near AID promoter.  A. This diagram 
shows the position and sequence of the PU.1-IRF composite binding site within the AID gene.  The 
sequence after mutation is shown below.  The foreign sequences are italicized.   The exon-intron 
organization of AID gene (AID-WT) is drawn to scale, and exon numbers are shown.  The diagram 
for AID-∆ illustrates the inactive allele of AID, in which exons 3 and 4 are eliminated.  B. The PU.1-
IRF binding site mutant is analyzed with Northern blotting.  The genotypes are indicated at the top, 
and “m” in the superscript represents the binding site mutation in the wild-type (AID
m/∆
) allele of the 
AID gene.  The top autoradiograph was hybridized with an AID cDNA probe, which revealed two 
bands.  The upper band corresponds to the wild-type AID transcript (AID-WT), while the lower band 
corresponds to the transcript from the exon 3-4 deleted allele (AID-∆).  The same membrane was 
rehybridized with an EF-1α cDNA probe to normalize RNA loading.  The relative AID-WT level is 
plotted in the histogram, and the value for AID
+/+
 cells is set as 1.  Each genotype is represented by 
three samples and the error bar shows standard deviation. 
 
 
3.2.4 PU.1 and IRF4 interact with the AID gene. 
The Dam methylation assay [113] was adapted to examine direct interaction of 
PU.1 and IRF4 with the AID gene in DT40 cells.  The assay is based on the Dam 
A. 
AID-WT 
PU.1-IRF binding site 
5’-TCCTTTTCCCTTCCTGT-3’ 
5’-TCCAGATCCCC-LoxP-GGGGATCTGATATCATCGATCCTGT-3’ 














AID+/+ AID+/∆ AIDm/∆ 
Relative AID-WT transcript level 
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methyltransferase from E. coli, which methylates adenine in the context of GATC.  
There is no equivalent enzyme in eukaryotic cells.  Introduction of Dam into eukaryotic 
cells leads to methylation of GATC motif throughout the genome.  When Dam is fused 
to a DNA-binding protein, the fusion protein preferentially methylates GATC in the 
region associated with the DNA-binding protein, and this property has been employed 
successfully to study protein-DNA interactions in vivo [114].  In comparison with 
Chromatin Immuno-Precipitation (ChIP), the advantage of the Dam methylation assay is 
that it does not require an antibody against the protein of interest.  Additionally, 
methylation within GATC motif can be conveniently detected and quantified with 
methylation-sensitive restriction enzymes.  The drawback of this method is that Dam 
could potentially affect the DNA-binding property of its fusion partner. 
In initial trial of the methylation assay, the Dam-PU.1 fusion protein methylated 
the AID gene with similar efficiency as control loci, such as EF-1α (data not shown).  
The outcome is not particularly surprising, since Dam is expected to methylate GATC 
independent of the fusion partner, and the non-targeted methylation activity may be so 
high as to obscure the effect of recruitment by PU.1.  To solve this problem, we 
introduced a point mutation, R95A, into the Dam gene.  According to the crystal 
structure of Dam/DNA complex, R95 contacts the phosphates of target DNA, and 
stabilizes the interaction of Dam with cognate DNA in a base non-specific manner [115].  
It is possible that changing R95 to a non-basic residue would reduce the DNA binding 
affinity of Dam without altering its target specificity.  Such attenuated Dam would be 
more dependent on a fused DNA-binding protein to interact with DNA, thus improving 
the specificity of the assay.   
To test this idea, we generated the Dam(R95A) mutant and evaluated its activity 
by complementing a dam
-
 E. coli strain.  Consistent with expectation, the mutation 
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substantially reduced the methylation activity of the enzyme, and the mutant Dam 
remains specific for GATC motif (data not shown).  This result encouraged assessment 
of the performance of this attenuated Dam in methylation assays in DT40 cells in the 
hope of improving the specificity of the method.  The attenuated Dam(R95A) was used 
in all the following experiments, and the mutation (R95A) is omitted for simplicity. 
The DNA-binding domain of PU.1 is at the C-terminal part of the polypeptide.  
In the fusion, the Dam enzyme was fused to the N-terminus of PU.1 (Dam-PU.1) to 
minimize potential interference with the DNA-binding activity of PU.1.  For IRF4, since 
the DNA-binding domain is at the N-terminal region of the polypeptide, Dam was linked 
to the C-terminus of IRF4 for the same reason.  Free Dam serves as the control for 
untargeted methylation activity in the experiments.   The cDNAs were expressed in 
DT40 cells with a tamoxifen-inducible system (Fig. 3.4A).  In the expression construct, 
the Dam or Dam fusion cDNAs are positioned downstream of the gpt drug selection 
marker, which was used for the selection of stable clones.  The gpt cDNA is positioned 
between the promoter and the Dam gene, and precludes the expression of Dam.  To 
initiate methylation, the cells were treated with tamoxifen, which activates the Cre 
recombinase produced from a transgene in the DT40 cell line.  The Cre recombinase 
catalyzes the excision of the gpt cDNA via flanking loxP sites, and the Dam cDNA is 
consequently positioned immediately downstream of the promoter for expression.  After 
24 or 48 hours of tamoxifen treatment, genomic DNAs were isolated, and the methylation 
pattern was analyzed by restriction digests with MboI, which only cleaves unmethylated 
GATC (Fig. 3.4B-D).    
The methylation status of the AID gene was compared with two housekeeping 
genes, EF-1α and hsc70, which are not regulated by PU.1 or IRF4.  For the AID gene, a 
1-kb restriction fragment that contains the promoter as well as the PU.1-IRF4 binding site 
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was examined, and the comparable promoter regions of EF-1α and hsc70 gene were 
analyzed as controls.  In cells containing free Dam, all three genes are methylated and 
the extent of methylation correlates with the duration of Dam expression.  The hsc70 
probe cross-hybridizes to an unknown fragment (* in Fig. 3.4D), which could be derived 
from a related heat shock gene family member.  This unknown fragment also appears 
accessible to Dam methylation as indicated with the generation of a longer fragment in 
response to Dam expression (the upper band of *, Fig. 3.4D).  Thus, free Dam 
methylates these loci in a largely indiscriminate fashion as expected.   
A different pattern was observed for Dam-PU.1 fusion, which preferentially 
methylates the AID 5’ region (Fig. 3.4B) relative to EF-1α (Fig. 3.4C), hsc70 and the 
cross-hybridizing fragment (Fig. 3.4D).  We believe methylation pattern reflects specific 
association of PU.1 with the AID gene, in consistent with its role in AID expression.  
The IRF4-Dam fusion methylates the AID locus (Fig. 3.4B), but not the hsc70 locus (Fig. 
3.4D).  However, the fusion also methylates the EF-1α locus (Fig. 3.4C) and the hsc 
cross-hybridizing fragment (Fig. 3.4C) to a substantial degree.  The high background 
makes it difficult to draw a firm conclusion regarding the specificity of IRF4 toward the 
AID locus.   
If Dam-PU.1 is recruited to the AID locus, why does the fusion protein methylate 
AID gene less efficiently than the free Dam (Fig. 3.4B)?  The apparent paradox could be 
explained if the intrinsic methylation activity of Dam is reduced in the context of the 
fusion.  The point can be illustrated with the methylation pattern at the EF-1α and hsc70 
loci.  Methylation at these loci is expected to reflect the intrinsic activity of Dam or its 
fusions, and the free Dam is clearly more active than the fusion proteins.  Given this 











gpt Dam PU.1 
cre 
Dam PU.1 




0 24 48 0 24 48 0 24 48 (hr) tamoxifen 







0 24 48 0 24 48 0 24 48 (hr) tamoxifen 
Dam Dam-PU.1 IRF4-Dam 
BglII BamHI MboI MboI 
Probe 
D. 
0 24 48 0 24 48 0 24 48 (hr) tamoxifen 
































Figure 3.4.  Methylation assay for the interaction of PU.1 and IRF4 with the AID gene.  A. This 
diagram illustrates the tamoxifen-inducible expression constructs for Dam and Dam fusions.  B. The 
autoradiograph is Southern analysis of the methylation pattern at the AID 5’ region.  The source of 
the DNA and tamoxifen induction time is indicated at the top of the autoradiograph.  The identity 
and the expected size of the restriction fragments are shown to the right of the blot.  E1 represents the 
first exon of AID gene.  The PU.1-IRF composite binding site is represented with a black circle.  
The location of the probe for the Southern analysis is indicated above the restriction map.  C. The 
autoradiograph shows Southern analysis of the methylation pattern at the EF-1α 5’ region.  All the 
labels of this panel are analogous to B.  D. The autoradiograph is Southern analysis of the 
methylation pattern at the hsc70 5’ region.  The symbol “*” marks a cross-hybridizing restriction 




The experiments presented in this chapter show that both PU.1 and IRF4 are 
involved in regulating AID gene expression, but PU.1 plays a more prominent role 
relative to IRF4.  Based on the Dam methylation analysis, PU.1 likely interacts directly 
with the AID gene to regulate its expression.  The role of a consensus PU.1-IRF binding 
site was examined near the promoter of AID gene, and found that the binding site 
mediates only a minor part of the PU.1 function.  Further studies are needed to identify 
other binding sites for PU.1 in the AID gene.   
PU.1 is capable of binding to the GGAA motif by itself, and such motifs are 
found in AID genes.  However, the short consensus is widespread in the genome, and it 
seems unlikely that the GGAA motif alone would be sufficient for specifying the location 
of PU.1 function.  Most likely, the function of PU.1 involves collaboration with factors 
other than IRF4, but the identity of such novel cofactors remains to be established.  One 
candidate factor is IRF8, which is the closest relative of IRF4 and is expressed in DT40 
cells (data not shown).  IRF8 can also form a complex with PU.1 and binds to the EICE 
site in target gene [105].  Moreover, IRF8 has also been observed to bind to a novel type 
of composite Ets-IRF binding site, where the order of the PU.1 and IRF motifs are 
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reversed relative to the typical EICE, and such kind of binding site has been named IECS 
[105].  There is indeed such an IECS motif near the promoter of the AID gene, but its 
function remains to be evaluated in future experiments.  Additionally, inactivation of the 
IRF8 gene in DT40 cells would help to test the role of this factor in regulating AID 
expression as well as other aspects of AID function.   
PU.1 may also function with factors other than IRF4 and IRF8, and the 
identification of PU.1 interaction proteins via affinity purification or yeast two hybrid 
approaches could potentially shed light on this issue.  Once we have identified any 
candidate factor, we could evaluate its function by genetic experiments as presented in 
this chapter.  Our data also cannot rule out an indirect role of PU.1 in regulating AID 
expression, since PU.1 has been shown to regulate the expression of many genes 
involved in hematopoietic cell differentiation.  Microarray analysis of PU.1-deficient 
cells relative to wild-type cells would be informative in this respect.    
Our results have revealed a clear difference in the regulation of AID expression 
between chicken and mouse B cells.  As described earlier, conditional ablation of PU.1 
in mouse B cells does not affect AID-mediated class switching and somatic 
hypermutation; on the other hand, loss of IRF4 in mature B cells leads to an obvious 
reduction in AID expression.  The situation is completely different in chicken B cells, 
where PU.1 appears to be more important than IRF4 with respect to the expression of 
AID.  Several other transcription factors have been implicated in the regulation of AID 
expression in mouse B cells, including Pax5, STAT6, NF-κB, and HoxC4.  However, 
the binding sites for these factors are not conserved between chicken and mouse AID 
promoters, and loss of NF-κB family members, p50 and c-Rel, has no impact on AID 
expression [65].  Most likely, the regulation of AID expression is different between 
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chicken and mouse, which is consistent with the fact that bursa is an organ unique to 
avian species with no mammalian counterpart.     
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Chapter 4  
IRF4 and PU.1 are important for AID-mediated gene conversion. 
4.1 RESULTS 
4.1.1 Gene conversion defect in IRF4-deficient DT40 cells. 
PU.1 and IRF4 may have roles beyond the regulation of AID expression.  As 
described earlier, a consensus PU.1-IRF binding site was found in an enhancer at the Igλ 
locus, and this binding site is conserved in the Igλ locus in the mouse and human 
genomes.  It is therefore possible that the two proteins also facilitate AID function at the 
Igλ locus, potentially by recruiting AID to the locus to mediate gene conversion.  Thus, 
it would be of interest to examine AID-mediated gene conversion activity in PU.1 and 
IRF4 deficient cells.  This experiment is not feasible in PU.1-deficient cells since AID 
expression is very low, and gene conversion is almost certainly defective.  On the other 
hand, the reduction of AID expression in IRF4-deficient cells is relatively mild, which 
enables us to test the impact of IRF4 deficiency on AID function in these cells.   
For this purpose, a gene conversion substrate was generated to determine gene 
conversion activity in IRF4-deficient cells (Fig. 4.1A).  The substrate reporter is derived 
from the puromycin-resistance gene (puro) that is inactivated by the insertion of an 
oligonucleotide (see Material and Methods and Fig. 4.1A).  The defective puro can be 
rescued through gene conversion, using an upstream fragment of puro as the donor 
template, and the percentage of puromycin-resistant cells represents gene conversion 
frequency [65].  In many studies, change in surface IgM expression, as measured with 
flow cytometry, was used as an assay for immunoglobulin gene conversion.  Relative to 
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flow cytometry, the drug selection method is more sensitive, which enables quantification 
of low frequencies of gene conversion in mutant backgrounds.   
The gene conversion substrate was integrated into a location downstream of the 
C region of the Igλ locus (for exact position of the integration site, see Materials and 
Methods) in both wild-type and IRF4-mutant cells.  In a previous report, the substrate 
was shown to undergo AID-mediated gene conversion when integrated at this location 
[65].  An obvious decrease in gene conversion activity was observed in IRF4
-/-/-
 cells 
relative to wild-type cells (compare f, g, h with a, Fig. 4.1B).  Moreover, the dosage of 
IRF4 gene appears to influence gene conversion activity, which is noticeably reduced in 
cells with one copy of the IRF4 gene (d and e, Fig. 4.1B).  Since AID function requires 
active transcription of the target DNA, the transcription status of the reporter was 
examined; no difference between wild-type and IRF4 deficient cells was observed (a, b, 
d, and f in Fig. 4.1C).  Therefore, IRF4 regulates AID-mediated gene conversion rather 
than transcription of AID target gene in a dosage-dependent manner. 
As observed earlier, AID expression is variable among different subclones of 
IRF4-deficient cells.  Similarly, we observed substantial variations in gene conversion 
activity among the three IRF4
-/-/-
 clones in gene conversion assays, and this variation 
seems to correlate with the level of AID expression among these subclones.  However, 
the severe gene conversion defect of the IRF4-deficient cells is unlikely attributable 
entirely to the reduction in AID expression.  In one of the subclone, AID is expressed at 
approximately 60% the level of wild-type cells, which is comparable to that in AID
+/-
 
cells.  The gene conversion activity in the AID
+/-
 cells is reduced by about 2-fold 
relative to wild-type cells (i in Fig. 4.1B), which is less severe compared to that observed 





Figure 4.1.  IRF4 deficiency impairs AID mediated gene conversion.  A. This diagram illustrates 
the gene conversion substrate.  Puro-fr represents the fragment of puromycin resistance gene that 
serves as the donor in gene conversion.  Puro-mu represents the mutated puro reporter before gene 
conversion, whereas Puro-WT represents the wild-type puro reporter after gene conversion.   B. The 
dot plot presents the gene conversion analysis of cells with different copy numbers of IRF4 genes.  
Each IRF4 mutant is represented with two or three clones (IRF
+/+/-
: b and c; IRF
+/-/-
: d and e; IRF
-/-/-
: f, 
g, and h).  Each dot represents result from one experiment (for colony numbers, see Table 1).  In 
two experiments for clone f, no puromycin-resistant colonies were observed, and these data points are 
shown below the baseline of the plot.  The bar represents the median GC frequency of a data set of at 
least six experiments, and the value is written below the plot.  C. The transcript levels of the puro 
reporter in various cell lines are analyzed with Northern blotting.  The same blot was rehybridized 
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Table 1. Gene conversion analysis of the IRF4 mutant cells. 
Puro Control GC
 
 Puro Control GC 
Genotype 
a b c d e  
Genotype 
a b c d e 
28 68 2.1x10
-3 
 0 41 0 
42 70 3.0x10
-3 
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25 42 6.0x10
-4 
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a: puromycin (puro)-resistant colony number; b: total number of cells distributed into 
media containing puromycin; c: colony number in media without puromycin (control); d: 
total number of cells distributed into media without puromycin; e: gene conversion 




To test whether the IRF4 function is specific for AID, the effect of IRF4 
deficiency on I-SceI mediated gene conversion was examined.  I-SceI is a homing 
endonuclease that is capable of introducing a double-stranded DNA (dsDNA) strand 
break within an 18-bp recognition sequence.  The puro reporter in the substrate contains 
an I-SceI recognition sequence, and cleavage at this site by I-SceI ought to induce gene 
conversion that is independent of AID [116].  An I-SceI expression construct (Fig. 4.2A) 
was introduced into both wild-type and IRF4-deficient cells that contain the gene 
conversion substrate.  Both alleles of the AID gene were inactivated in these cells (Fig. 
4.2B) so that gene conversion relies exclusively on I-SceI.  In fact, the I-SceI expression 
construct was integrated into the AID gene.  This way, both wild-type and IRF4-
deficient cells contain a single copy of the I-SceI transgene at the same genomic location, 
which would ensure comparable levels of I-SceI expression in the two cell types.  The 
expression of I-SceI cDNA was controlled with the same tamoxifen-inducible system 
employed for the methylation experiments (Fig. 4.2A).  The inducible system prevents 
gene conversion before tamoxifen induction (Table 2).  Addition of tamoxifen to the 
cells readily induced I-SceI expression (Fig. 4.2B), and similar levels of gene conversion 
was observed in wild-type and IRF4-deficient cells (Fig. 4.2C).  Thus, IRF4 is 
dispensable for I-SceI mediated gene conversion, and it is specifically required for 





Figure 4.2.  IRF4 is dispensable for I-SceI-mediated gene conversion.  A. The diagram illustrates 
the tamoxifen inducible expression construct for I-SceI.  B. The top panel of Northern blotting shows 
that AID is not expressed in the cells containing the I-SceI expression construct.  DT40 cells without 
the construct serves as control.  The middle panel of Northern blotting shows that I-SceI expression 
is induced with tamoxifen.  The band marked with * is most likely a readthrough transcript due to 
incomplete polyadenylation downstream of the gpt.  The bottom panel of Northern blot is hybridized 
with an EF-1α cDNA probe to normalize RNA loading.  C. The dot plot compares the frequency of I-
SceI-mediated gene conversion in wild-type versus IRF deficient cells.  The bar indicates the median 
GC frequency of a data set of seven experiments, and the value is written below the plot (for colony 
















































Table 2. I-SceI mediated gene conversion in IRF4 deficient cells. 
Puro Control GC 
Genotype 
























0 26 0 
0 28 0 
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a, b, c, d, e are defined as in Table 1. 
 
 
4.1.2 A gene dosage effect of PU.1 on AID-mediated gene conversion.  
In PU.1-deficient cells, AID expression is dramatically reduced, which precludes 
the evaluation of AID-mediated gene conversion activity in this cell line.  However, 
AID expression is normal in PU.1
+/-
 cells, and in light of the gene dosage effect of IRF4 
on AID-mediated gene conversion, it is possible that a gene conversion defect could be 
observed in PU.1
+/-
 cells as well.  Using the same gene conversion substrate, the gene 
conversion activity in PU.1
+/-
 cells was analyzed, and, unexpectedly, an approximately 
20-fold reduction in gene conversion frequency was observed (Fig. 4.3A).  Moreover, 
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the transcription level of the substrate is not affected in PU.1
+/-
 cells.  Therefore the 
phenotype is not an indirect consequence of defect in transcription (Fig. 4.3B).   
 
 
Figure 4.3.  PU.1 deficiency impairs AID-mediated gene conversion.  A. The dot plot presents the 
gene conversion analysis of wild-type and PU.1 heterozygous cells.  Each dot represents result from 
one experiment (for colony numbers, see Table 3).  In one experiment for clone f, no puromycin 
resistant colonies were observed, and this data point is shown below the baseline of the plot.  The bar 
represents the median GC frequency of a data set of at least six experiments, and values are written 
below the plot.  B. The transcript levels of the puro reporter in both cell lines were analyzed with 
Northern blotting.  The same blot was rehybridized with an EF-1α cDNA probe to normalize RNA 
loading.  
 


































































































a, b, c, d, e are defined as in Table 1. 
 
 
To address whether the gene conversion defect is specific to AID, the I-SceI 
mediated gene conversion system was applied to PU.1
+/- 
cells.  In contrast to the severe 
reduction in AID-mediated gene conversion, I-SceI mediated gene conversion is in fact 
increased by about 3-fold in PU.1
+/-
 cells (Fig. 4.4).  The reason behind the increase in I-
SceI mediated gene conversion in PU.1
+/-
 cells is presently unclear, but the result clearly 
shows that the gene conversion defect is specific for AID.  Thus, PU.1 is important for 
AID-mediated gene conversion at the Ig locus, and moreover, the dosage of PU.1 is 





Figure 4.4.  PU.1 is dispensable for I-SceI mediated gene conversion.  The dot plot compares the 
frequency of I-SceI mediated gene conversion in wild-type versus PU.1 heterozygous cells.  The bar 
indicates the median GC frequency of a data set of at least six experiments (for colony numbers, see 
Table 4), and the value is written below the plot. 
 
Table 4. I-SceI mediated gene conversion in PU.1 heterozygous cells. 
Puro Control GC 
Genotype 
























0 26 0 
0 28 0 







































































a, b, c, d, e are defined as in Table 1. 
 
 
4.1.3 Gene conversion defect in PU.1-IRF binding site mutants at the Igλ locus. 
IRF4 and PU.1 could facilitate AID function by recruiting it to the Igλ locus or by 
increasing local chromatin accessibility, and both mechanisms would require that IRF4 
and PU.1 associate with the Igλ locus directly.  The two PU.1-IRF composite binding 
sites within the 2.4-kb regulatory region may mediate this association.  To evaluate their 
function, both binding sites were mutated through homologous recombination (Fig. 
4.5A), and the gene conversion substrate was integrated into the Igλ locus (Fig. 4.5A) 
with (j, Fig. 4.5B) or without (a, Fig. 4.5B) the binding site mutations.  Mutation of the 
PU.1-IRF binding sites reduces gene conversion frequency by approximately 3-fold 
(compare j with a in Fig. 4.5B).  The relatively mild effect of the mutation could be due 
to the presence of potentially redundant elements in the Igλ locus, which is known to 
contain multiple regulatory elements.  To address this possibility, a 7.4-kb region 
(Region B, Fig. 4.5A and B) downstream of the PU.1-IRF binding sites was deleted.  
Deletion of this 7.4-kb region leads to a 4-fold reduction in gene conversion (k, Fig. 
4.5B).  Introduction of the binding site mutation into this deletion background decreases 
gene conversion further by approximately 5-fold (compare l with k, Fig. 4.5B).  Thus, in 
the absence of redundant regulatory elements, gene conversion is more dependent on the 
PU.1-IRF4 binding sites.  The binding site mutation does not have major impacts on the 
transcription of the substrate (compare j with a, l with k, Fig. 4.5C).  Therefore, the gene 
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Figure 4.5.  PU.1-IRF composite binding sites in the Igλ locus are involved in AID-mediated gene 
conversion.  A. This diagram shows the location (filled circle) and sequence (underlined) of the two 
PU.1-IRF composite binding sites in the rearranged allele of Igλ.  The two binding sites differ in the 
relative order of the PU.1 and IRF binding motifs.  The mutations are italicized.  The diagram of 
Igλ is drawn to scale.  L, VJ, and C represent the leader exon, rearranged VJ region, and constant 
region, respectively.  The integration site for the gene conversion substrate is marked with an 
arrowhead.  B. The four gene conversion substrates (a, j, k, and l) differ in mutation of the PU.1-IRF 
binding site (open circle) and deletion of Region B (bracket).  The gene conversion frequencies of 
these four substrates are presented in the dot plot.  The data for a is the same shown in Fig. 4.1B.  
Each dot represents results from one experiment (for colony numbers, see Table 5).  The bar 
represents the median gene conversion (GC) frequency of a data set of at least six experiments, and 
value is written below the plot.  C. The transcript levels of the puro reporter in various cell lines are 
analyzed with Northern blotting.  The same blot was rehybridized with an EF-1α cDNA probe to 
normalize RNA loading. 
 
 
Table 5. Gene conversion analysis of PU.1-IRF binding site (BS) mutants. 
Puro Control GC  Puro Control GC 
Genotype 
a b c d e  
Genotype 
a b c d e 
28 68 2.1x10
-3 
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4.1.4 Interaction of PU.1 and IRF4 with the Igλ locus. 
The phenotype of the PU.1-IRF binding sites mutations is consistent with the 
possibility that both proteins interact with the Igλ locus.  To address this issue in a more 
direct manner, the Dam methylation assay again was used with region A that contains 
both of the composite PU.1-IRF binding sites (Fig. 4.5A).  There are restriction site 
polymorphisms between the two alleles of Igλ in this region, which enables us to 
distinguish them in Southern analysis (Fig. 4.6).  Both Dam-PU.1 and IRF4-Dam 
efficiently methylate the regulatory region on both alleles of Igλ (Fig. 4.6), and the extent 
of methylation appears to be higher relative to EF-1α (Fig. 3.4C), hsc70 and the cross-
hybridizing fragment (Fig. 3.4D).  This result suggests that both PU.1 and IRF4 interact 




Figure 4.6.  Methylation analysis of the interaction of PU.1 and IRF4 with Region A in the Igλ 
locus.  The autoradiograph is a Southern analysis of the methylation pattern in Region A.  The 
sample in the first lane is digested with EcoRI and SacI, but without MboI, to illustrate the restriction 
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4.2 DISCUSSION 
The experiments presented in this chapter address the roles of PU.1 and IRF4 in 
AID-mediated gene conversion at the Igλ locus.  Deficiencies were shown in either 
PU.1 or IRF4 impair AID-mediated gene conversion, and the dosage of PU.1 appears to 
be critical in this respect.  Two composite PU.1-IRF binding sites were found in a 
regulatory region in the Igλ locus, and the roles of these two binding sites in AID-
mediated gene conversion were addressed.  Elimination of these two PU.1-IRF binding 
sites impairs AID function at the locus, suggesting that these binding sites may indeed 
mediate, at least in part, the functions of PU.1 and IRF4.  Consistent with this 
possibility, both PU.1 and IRF4 appear to interact directly with the regulatory region 
based on methyltransferase recruitment assays.  On the other hand, the gene conversion 
defect observed in the binding site mutations is less severe compared with IRF4 and PU.1 
deficient cells.  The discrepancy suggests that these two factors have additional 
functions, which may involve collaboration with other factors through additional binding 
sites.  As described previously, E2A and NF-κB have also been implicated in AID 
mediated gene conversion.  Moreover, the Igλ regulatory element contains binding sites 
for the transcription factors, Octamer binding proteins and Mef2; mutations of these 
binding sites have been shown to impair the function of this regulatory element in 
targeting AID function to ectopic sites [65].  All of these factors could potentially 
collaborate with PU.1 and IRF4.  In fact, E2A is known to bind to the mouse Igκ 3’ 
enhancer synergistically with IRF4 [106].  The potential collaboration of PU.1 and IRF4 
with the other factors remains to be evaluated. 
The next important question is how PU.1 and IRF4 facilitate AID function.  
Since both factors can function as transcriptional activators, they may help to open up the 
local chromatin structure and facilitate the access of AID to target DNA.  However, the 
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results from the I-SceI gene conversion experiments seem to be inconsistent with the 
explanation.  The gene conversion reaction is initiated by the endonuclease cleavage of 
the target site, and the cleavage efficiency is expected to correlate with the accessibility 
of target DNA.  If deficiency in IRF4 or PU.1 leads to a reduction in chromatin 
accessibility at the Igλ locus, a reduction in I-SceI mediated gene conversion would be 
expected, which is not the case.  The caveat of this argument is that gene conversion is 
an indirect readout of I-SceI cleavage activity.  The cleavage product by Southern 
analysis could not be observed, presumably because of low abundance and transient 
nature of the double strand break.  In future experiments, DNase I hypersensitivity 
assay, methylation assay and histone modification status may further address this issue. 
PU.1 and IRF4 could also function by recruiting AID to the Igλ locus, potentially 
through direct interaction with AID.  As discussed in chapter 1, RPA is the only factor 
that previously has been shown to interact with AID, but this interaction is unlikely to be 
sufficient to explain the target specificity of AID.  Since PU.1 and IRF4 can recognize 
binding sites in the Igλ locus, they would fit the requirement for the specific AID-
recruiting factor, and they may achieve this function through collaboration with 
additional factors, such as E2A.  It is possible that the recruitment of AID may involve a 
multi-protein complex rather than single factors, which may explain the difficulty in 
identifying a specific AID recruitment factor.   
Applying the methylation recruitment assay to AID localization, preliminary 
evidence has been obtained that AID is indeed preferentially targeted to the Igλ locus, 
and this recruitment requires the regulatory element that contains the PU.1-IRF binding 
sites (Kim and Tian, unpublished observations).  In future experiments, this approach 
could be used to address whether PU.1 and IRF4 are important for recruiting AID to the 
Igλ locus.  If these factors do play a role in targeting AID, potential direct interactions 
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between AID and these factors could be tested, either by themselves or together with 
other factors such as E2A.  Moreover, affinity purification approaches could be used to 
isolate proteins associated with AID or PU.1 and IRF4 to see if these proteins exist in a 
common complex, and if so, what other proteins are within this complex.  The 
advantage of the system is that, once a candidate factor or association is detected, its 
functional relevance could be evaluated by genetic experiments.  
PU.1 and IRF4 could also regulate AID function by other indirect means, for 
example by controlling the expression of other factors involved in AID function.  In 
mice, PU.1 and IRF4 control the expression of many factors involved in B-cell 
differentiation.  The same could be true in chicken B cells.  This might explain the 
severe defect in gene conversion observed in PU.1
+/- 
cells.  It is possible that function of 
PU.1 is counter balanced by competing factors, which would favor an alternative cell fate 
that is incompatible with AID function.  In such a scenario, the dosage of PU.1 could be 
critical since a small change in PU.1 could tip the balance between the two competing 
cell fates and strongly influence AID function.  This issue could be addressed by 





for example by microarray analysis.  As described in chapter 3, such experiments may 
also help to understand how PU.1 regulate the expression of AID, since it remains 
possible that PU.1 may stimulate AID expression, at least in part, by controlling the 
expression of other factors involved in AID gene transcription. 
An intriguing observation made in this part of the experiments is that there seems 
to be a reciprocal relationship between AID and I-SceI-mediate gene conversion in 
PU.1
+/-
 cells.  Whereas AID-mediated gene conversion is reduced in PU.1
+/-
 cells, I-
SceI-mediated gene conversion is increased in the same cell type.  The difference is 
consistent, and does not appear to simply represent experimental variation.  Moreover, 
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the same reciprocal relationship was observed when the same approach was used to 
compare the effect of deleting the Igλ regulatory region on AID versus I-SceI-mediated 
gene conversion (Kim and Tian, unpublished observations).  In those experiments, 
deletion of the Igλ regulatory element strongly impairs AID-mediated gene conversion, 
but I-SceI mediated gene conversion appears to be more efficient in the absence of the 
regulatory element, a result analogous to that observed in PU.1
+/-
 cells.  At present, we 
do not have a satisfactory explanation for this unusual phenomenon.   
In broad terms, it is possible that the regulatory element and PU.1 are involved in 
recruiting certain factors to the Igλ locus that facilitate AID function, and these factors 
interfere with I-SceI cleavage of target DNA, potentially by competing for the interaction 
with target DNA.  Another possibility is that the regulatory element and PU.1 help to 
unwind target DNA.  As discussed in chapter 1, AID can only deaminate cytosines in 
the context of single-stranded DNA.  By contrast, I-SceI can only cleave double-
stranded DNA.  So, there is mutually exclusive relationship between the two enzymes in 
terms of their substrate requirements.  It is possible that the regulatory element and PU.1 
may modify the transcription apparatus in a way that allows it more effective unwinding 
of template DNA.  Another possibility is that the regulatory element and PU.1 are 
required for high levels of transcription elongation through the target DNA, which would 
increase the extent of DNA unwinding.  Although obvious reductions in the steady state 
transcript levels of the gene conversion substrate were not observed in the absence of 
PU.1, IRF4, or the regulatory element, it remains possible that the actual numbers of 
RNA polymerases engaged in elongation on the template DNA is reduced under the 
circumstances.  This issue could be resolved by performing Chromatin Immuno-
Precipitation (ChIP) analysis on RNA polymerase II or nuclear run-on analysis.   
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Appendix 
The homologous recombination defects in PU.1-deficient cells 
A.1 BACKGROUND 
One unique feature of DT40 is the high ratio of homologous targeting events 
versus random integration events [112], but the molecular basis for this phenomenon is 
presently unclear.  The high levels of homologous recombination probably reflect the 
need of the bursa B cells to perform gene conversion, which is mediated by the 
homologous recombination machinery.  Broadly speaking, the high ratio of homologous 
targeting efficiency could be the consequence of either elevated levels of homologous 
recombination or reduced levels of non-homologous end joining, which is responsible for 
random integration; the two recombination pathways occur through completely different 
mechanisms and involve distinct factors.   
Homologous recombination is generally initiated by a double-stranded DNA 
break [117].  The 5’ end of the double-strand break is then resected by exonucleases to 
generate a 3’ ended single-stranded tail [117].  The homologous recombination 
machinery catalyzes the invasion of this 3’ tail into a homologous duplex to initiate 
strand exchange [117].  The strand exchange intermediate could eventually be resolved 
by various pathways, such as Holiday junction resolvase, to generate the recombination 
product [117].  By comparison with the elaborate pathway of homologous 
recombination, non-homologous end joining is achieved by the straight ligation of DNA 
ends from double stranded breaks [118].  It is possible that DT40 may simply have 
higher levels of the factors involved in homologous recombination or lower levels of the 
factors responsible for non-homologous end joining.  Alternatively, DT40 may have 
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novel factors that either up-regulate homologous recombination or repress non-
homologous end joining.  No concrete evidence supporting any of these scenarios has 
been reported so far.   
My interest in this problem stems from the unexpected finding that the gene 
conversion substrate could not be integrated into the Igλ locus of PU.1
-/-
 cells through 
homologous targeting, which is usually an efficient event in wild-type DT40 cells (Table 
6).  The question is: do PU.1
-/-
 cells have a generalized defect in homologous 
recombination?  If so, does PU.1 control the expression of the factor that is responsible 
for the unusual property of DT40 cells in terms of high homologous targeting ratio 
relative to random integration?  In the following section, I present preliminary 
experiments to address these issues.  
 
A.2 RESULTS AND DISCUSSION 
As described above, the gene conversion substrate could not be stably integrated 
into the Igλ locus of PU.1
-/-
 cells.  The problem is not caused by inefficient transfection 
since stable integrants that contain the transfected construct were obtained; but all of the 
integration events were random.  To test whether this phenomenon is specific to this 
targeting construct, a different targeting construct was designed to integrate into a 
different location in the Igλ locus (Table 6).  In wild-type DT40 cells, 8 out of 24 
screened colonies integrated the construct into the Igλ locus.  By contrast, none of the 
24 transfectants of PU.1
-/-
 cells contain homologous integration with the same construct.  
Thus, the problem is not unique to one particular construct or transfection event. 
The targeting defect was analyzed for loci other than Igλ and to determine if there 
was a general defect in homologous recombination.  Toward this end, the homologous 
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targeting efficiency was tested at two other genes: CBP and p300, which encode 
transcription coactivators.  In wild-type DT40 cells, these targeting constructs integrate 
into their homologous targets at 50% frequency (Table 6).  In PU.1
-/-
 cells, the targeting 
frequencies at these two loci depend on the way the targeting constructs were linearized 
prior to transfection (Table 6).  When the construct was linearized with PvuI, which 
generates a 3’ protruding end, the targeting frequencies into either the p300 or the CBP 
locus was around 30% in PU.1
-/-
 cells.  By contrast, if the constructs were linearized 
with a restriction enzyme to produce a 5’ overhang, the frequency of homologous 
targeting at both loci was severely reduced.  This observation led us to redo the targeting 
experiments at the Igλ locus with a construct that was linearized with PvuI.  However, 
contrary to expectations, Igλ remains refractory to homologous targeting even under this 
situation.   
Moreover, the position of the linearization site at the targeting construct seems to 
affect the targeting efficiency as well (Table 6).  The linearization sites described so far 
are all within the cloning vector, and the construct was cleaved only once; for this reason, 
the heterologous vector sequence is still attached to the homology arms.  In the CBP 
locus, if the vector sequence was removed by restriction digestion on both sides of the 
homology arm, the targeting frequency was more than 90%, even though the restriction 
enzyme generates 5’ protruding ends, which previously gave poor targeting frequencies 
(Table 6).  By contrast, the same treatment for both the p300 and Igλ targeting 
constructs failed to improve the targeting frequency (Table 6).   
Thus, PU.1
-/-
 cells clearly exhibit certain defects in homologous targeting, but the 
defect is variable with respect to the targeted loci and the manipulation of the targeting 
construct.  The defect is most consistent at the Igλ locus, which failed to achieve 
homologous targeting with any of the constructs or linearization methods (Table 6).  At 
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the p300 and CBP loci, the targeting frequency depends on the linearization method of 
the targeting construct, and the same linearization method has different effects in the two 
loci.  At present, no satisfactory explanation for these observations has been obtained.  
Since homologous targeting works at least under some circumstances, the PU.1
-/-
 cells do 
not appear to have a generalized defect in homologous recombination.  Moreover, the 
expression levels of many homologous recombination factors in PU.1
-/-
 cells have been 
examined, but no difference relative to wild-type cells were found (data not shown).  
The locus dependence of the integration defect suggests that the problem may lie in the 
relative accessibility of the different loci to homologous recombination machinery.  It is 
possible that PU.1 is important for the access of homologous recombination machinery to 
the Igλ locus, and this function may be relevant to the regulation of Ig gene conversion.  
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a: Non-homologous sequences are retained on the targeting constructs after linearization. 
b: Non-homologous sequences are removed from targeting construct after linearization. 
c: On one experiment, there is a faint band for targeted allele on the Southern blot.  The 
sample for that experiment may contain more than one colony.  
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